Welcome to our dedicated page for ICON PLC news (Ticker: ICLR), a resource for investors and traders seeking the latest updates and insights on ICON PLC stock.
ICON plc (NASDAQ: ICLR) is a clinical research organisation headquartered in Dublin, Ireland, operating in the research and development in biotechnology industry. This news page focuses on company announcements and updates that relate to its clinical research activities, financial performance and corporate developments.
ICON’s news releases commonly cover quarterly financial results, including revenue, net income, adjusted EBITDA and related non‑GAAP measures. These updates often discuss business wins, book‑to‑bill ratios, cash generation and capital allocation decisions such as share repurchase activity, as reflected in the company’s second and third quarter 2025 results announcements.
Investors and industry observers can also find news about ICON’s participation in investor and healthcare conferences. The company regularly announces presentations at events such as global healthcare conferences and growth stock conferences, as well as the scheduling of earnings conference calls and webcasts. These items provide insight into how ICON communicates its strategy and performance to the market.
Corporate governance and leadership changes are another key news category. For example, ICON has announced a CEO transition, detailing succession planning and board decisions. The company also publishes the results of its annual general meeting, including shareholder votes on director elections, auditor ratification and share authorisations.
In addition, ICON highlights recognition of its clinical research capabilities, such as independent benchmarking reports that assess its performance in phase 1 clinical trials. News may also include updates on specific research programmes, such as vaccine study updates noted in its filings. For ongoing visibility into ICON plc’s operations, financial reporting and role as a clinical research organisation, this news feed aggregates company-issued information in one place.
ICON plc (NASDAQ: ICLR) reported robust financial results for Q4 2022 and the full year, showcasing strong operational performance. Net business wins were $2,350 million in Q4, with a record backlog of $20.7 billion, reflecting a 2.4% quarterly increase. Q4 revenue reached $1,962 million, a 4.3% rise from the previous year. Full-year revenue was $7,741.4 million, a significant 41.2% growth. Adjusted EBITDA for Q4 was $405 million, marking a 21.8% increase, while GAAP net income for the full year amounted to $505.3 million, translating to $6.13 per diluted share. The company reaffirmed its 2023 revenue guidance of $7,940 - $8,340 million.
ICON (NASDAQ: ICLR), a leading healthcare intelligence and clinical research organization, will release its financial results for Q4 2022 on February 22, 2023, after market close. A conference call to discuss the results will be held on February 23, 2023, at 8:00 am ET. The company, headquartered in Dublin, Ireland, employed approximately 41,150 employees across 113 locations in 53 countries as of September 30, 2022. Investors are advised that this release contains forward-looking statements subject to risks and uncertainties, and should not rely solely on them for investment decisions.
ICON plc (ICLR) has announced its financial guidance for the year ending December 31, 2023. Expected revenue ranges from $7,940 to $8,340 million, indicating a growth of 3.3% to 6.8% compared to 2022. Adjusted earnings per share are anticipated to be between $12.40 and $13.05, reflecting a growth of 6.4% to 10.1%. The company reaffirmed its 2022 guidance, projecting revenue of $7,690 to $7,810 million.
ICON plc (NASDAQ: ICLR), a leader in healthcare intelligence and clinical research, announced that CEO Dr. Steve Cutler will present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023, at 5:15 PM PST/8:15 PM EST. The conference will showcase key insights into ICON's operations and strategy. Changes to the event will be updated on the Investor Relations section of their website under 'Events'. With approximately 41,150 employees across 113 locations in 53 countries, ICON is committed to advancing clinical research and improving patient lives.
Summary not available.
On November 28, 2022, BetterInvesting Magazine announced Icon PLC (NYSE: ICLR) as its "Stock to Study" and Williams-Sonoma Inc. (NYSE: WSM) as its "Undervalued Stock" for the January-February 2023 issue. The initiative is aimed at enhancing investors' financial literacy and empowering informed investment decisions. BetterInvesting encourages potential investors to conduct thorough reviews using their online tools. The recommendations serve purely educational purposes and do not constitute endorsements for purchase.
ICON plc (NASDAQ: ICLR), a global leader in healthcare intelligence and clinical research, announced that CFO Brendan Brennan will present at the 2022 Evercore ISI HealthCONx Conference on November 30, 2022, at 08:00 am EST. The presentation will be available via live webcast. For updates and links to the webcast, visit the Investor section of ICON's website under 'Events'. As of September 30, 2022, ICON employed around 41,150 people across 113 locations in 53 countries, enhancing clinical research and patient care.
ICON plc (NASDAQ: ICLR) reported third quarter 2022 results showcasing strong financial performance. Net business wins reached $2,351 million, with a book-to-bill ratio of 1.21. Revenue for Q3 was $1,942.4 million, up 3.9% year-on-year. Year-to-date revenue hit $5,779.4 million, reflecting a 60.6% increase. Adjusted EBITDA stood at $379.6 million, representing 19.5% of revenue. Adjusted net income was $247.2 million, leading to $3.00/b per diluted share. The company reaffirmed its full-year guidance, anticipating revenue between
ICON plc (NASDAQ: ICLR) has been selected by the US Biomedical Advanced Research and Development Authority (BARDA) to conduct a clinical trial for the AV7909 anthrax vaccine. Funded by BARDA, this trial aims to evaluate the immune response of healthy adults to the next-generation vaccine, with activities including project management and clinical operations. ICON has significant experience in vaccine studies, participating in over 160 trials in the past five years. The trial will start in early 2023, addressing the potential threat of anthrax exposure.
ICON plc (NASDAQ: ICLR) will release its Q3 2022 financial results on November 2, 2022, post market close. A conference call will follow on November 3, 2022, at 8:00 AM ET to discuss the results. As of June 30, 2022, ICON employed approximately 40,500 staff across 119 locations in 53 countries. The firm emphasizes its role in advancing clinical research and patient care, but noted that forward-looking statements are subject to risks that could affect actual results. Further updates will be provided on the Investor Relations section of the ICON website.